Gates Foundation gives $220 mln for TB research

March 15, 2012
Microsoft billionaire Bill Gates and his wife are to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis, a company statement said Thursday.

Microsoft billionaire Bill Gates and his wife are to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis, a company statement said Thursday.

The Bill and Melinda Gates Foundation is donating the money to Aeras which from its bases in the United States and South Africa has developed six possible TB vaccines that are being tested across Africa, Asia, Europe and America.

"This infusion of funding must be seen as a global call to action in response to one of the world's deadliest diseases," said Jim Connolly, Aeras's president and chief executive, expressing gratitude for the massive grant.

"It will allow Aeras to expand upon existing partnerships in Europe, Africa, China, and around the world."

A total of 8.8 million people globally fell ill with the contagious in 2010 and around 1.4 million died, according to the (WHO).

Trevor Mundel, president of the global health program at the , said the development of successful vaccines "would be the single greatest advance in the global fight against TB."

Once known as "consumption" for the slow wasting away of the people who died of it, one out of every three people is thought to be infected by the airborne TB organism, though only a fraction go on to develop the disease.

The WHO estimates the global of TB is $12 billion a year, with India and China together accounting for more than half that cost.

Explore further: Gates Foundation goes after TB

Related Stories

Gates Foundation goes after TB

September 20, 2007

The Bill & Melinda Gates Foundation, based in Seattle, has announced $280 million in grants to fight a growing tuberculosis problem.

Groundbreaking, lifesaving TB vaccine a step closer

October 8, 2008

Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development ...

TB vaccine enters new clinical trials

April 23, 2009

(PhysOrg.com) -- The world’s leading candidate for a tuberculosis vaccine, developed at the University of Oxford, is to enter Phase IIb proof-of-concept clinical trials, making it the first TB candidate vaccine for more ...

New TB booster shows promise

March 16, 2010

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

Vaccine targeting latent TB enters clinical testing

December 1, 2011

Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease. The ...

Recommended for you

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.